Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242015072 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Sun Young Moon und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea. Hauptthemen laut MEDLINE: Immune Checkpoint Proteins, Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF), funded by the Ministry of Education, the Korea Polar Research Institute (KOPRI) grant funded by the Ministry of Oceans and Fisheries, Korea Polar Research Institute (KOPRI) grant funded by the Ministry of Oceans and Fisheries.
Abstract (Originalsprache)
Cancer immunotherapy strategies are based on the utilization of immune checkpoint inhibitors to instigate an antitumor immune response. The efficacy of immune checkpoint blockade, directed at adaptive immune checkpoints, has been demonstrated in select cancer types. However, only a limited subset of patients has exhibited definitive outcomes characterized by a sustained response after discontinuation of therapy. Recent investigations have highlighted the significance of immune checkpoint molecules that are overexpressed in cancer cells and inhibit myeloid lineage immune cells within a tumor microenvironment. These checkpoints are identified as potential targets for anticancer immune responses. Notably, the immune checkpoint molecules CD24 and CD200 have garnered attention owing to their involvement in tumor immune evasion. CD24 and CD200 are overexpressed across diverse cancer types and serve as signaling checkpoints by engaging their respective receptors, Siglec-10 and CD200 receptor, which are expressed on tumor-associated myeloid cells. In this review, we summarized and discussed the latest advancements and insights into CD24 and CD200 as emergent immune checkpoint moieties, further delving into their therapeutic potentials for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea.
- Research Unit of Cryogenic Novel Material, Korea Polar Research Institute, Incheon 21990, Republic of Korea.
- Department of Polar Sciences, University of Science and Technology, Incheon 21990, Republic of Korea.
ORCID-Profile: Jun Hyuck Lee
Förderung
- National Research Foundation of Korea (NRF), funded by the Ministry of Education
- the Korea Polar Research Institute (KOPRI) grant funded by the Ministry of Oceans and Fisheries
- Korea Polar Research Institute (KOPRI) grant funded by the Ministry of Oceans and Fisheries
Zitieren
APA
Moon, S. Y., Han, M., Ryu, G., Shin, S. A., Lee, J. H., & Lee, C. S. (2023). Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242015072
Vancouver
Moon SY, Han M, Ryu G, Shin SA, Lee JH, Lee CS. Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242015072
BibTeX
@article{Moon2023,
author = {Moon, Sun Young and Han, Minjoo and Ryu, Gyoungah and Shin, Seong-Ah and Lee, Jun Hyuck and Lee, Chang Sup},
title = {Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242015072}
}
EUVIMED